Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nivalis Therapeutics, Inc.
The number of patients with adverse events measured in both the treated and placebo groups from start of dosing until Day 28 post dose.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) between 18.5 and 35 kg/m2, inclusive, at screening.
Patient has a ≤ 5 pack years smoking history and nonsmoking for ≥ one year.
Documented history of mild bronchial asthma, first diagnosed at least 6 months and currently being treated only with intermittent short-acting beta-agonist therapy by inhalation.
Pre-bronchodilator FEV1 ≥ 75% of predicted at screening.
Sensitivity to methacholine with a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of ≤ 8 mg/ml at screening.
Demonstrated stable lung function during screening with ≤10% variability between two assessments of FEV1 taken at least 7 days apart at approximately the same time of day.
You may not be if
Hypertension at screening is defined as systolic blood pressure (BP) \>150 mmHg or diastolic BP \> 90mmHg.
Respiratory tract infection and/or exacerbation of asthma within prior 4 weeks
History of life-threatening asthma
Administration of steroids within 4 weeks of the screening visit.
History of being unable to tolerate or complete MCh testing.
Blood donation (500 mL) within 3 months of starting the clinical study.
Tested positive for hepatitis C antibody or hepatitis B surface antigen.
Tested positive for human immunodeficiency virus (HIV) antibodies.
Clareo Health | Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
